View Older Stories View More Recent Stories

Sep 11, 2017 08:01AM AbbVie's Upadacitinib (ABT-494) Meets All Primary and Ranked Secondary Endpoints in Second Phase 3 Study in Rheumatoid Arthritis
Sep 8, 2017 11:03AM AbbVie Declares Quarterly Dividend
Sep 7, 2017 08:57AM AbbVie Leads Biotechnology Industry on Dow Jones Sustainability Index for Second Consecutive Year
Sep 7, 2017 08:05AM AbbVie (ABBV) Says Upadacitinib Met Primary Endpoint in Phase 2b Study in Atopic Dermatitis
Sep 7, 2017 08:03AM AbbVie's Upadacitinib (ABT-494) Meets Primary Endpoint in Phase 2b Study in Atopic Dermatitis
Sep 7, 2017 07:30AM AbbVie to Present at the Morgan Stanley 15th Annual Global Health Care Conference
Sep 6, 2017 08:02AM AbbVie (ABBV) Submits NDA to FDA for Investigational Oral Treatment Elagolix for Management of Endometriosis with Associated Pain
Sep 6, 2017 08:01AM AbbVie Submits New Drug Application to U.S. FDA for Investigational Oral Treatment Elagolix for the Management of Endometriosis with Associated Pain
Aug 3, 2017 03:28PM AbbVie Receives U.S. FDA Approval of MAVYRET™ (glecaprevir/pibrentasvir) for the Treatment of Chronic Hepatitis C in All Major Genotypes (GT 1-6) in as Short as 8 Weeks
Aug 2, 2017 01:35PM Johnson & Johnson (JNJ) Announces FDA Approval for IMBRUVICA in Adults with cGVHD
Aug 2, 2017 01:12PM AbbVie (ABBV) Annouces FDA Approval of IMBRUVICA for Adults with cGVHD
Aug 2, 2017 01:07PM U.S. FDA Approves IMBRUVICA® (ibrutinib) as First Approved Treatment Specifically for Adults with Chronic Graft-Versus-Host-Disease (cGVHD) -- A Serious, Potentially Life-Threatening Condition -- Aft
Jul 28, 2017 10:57AM European Commission Grants AbbVie's MAVIRET® (glecaprevir/pibrentasvir) Marketing Authorization for the Treatment of Chronic Hepatitis C in All Major Genotypes (GT1-6)
Jul 28, 2017 07:42AM AbbVie Reports Second-Quarter 2017 Financial Results
Jul 21, 2017 09:37AM AbbVie (ABBV) Announces CHMP Positive Opinion for HUMIRA for Treatment of Pediatric Patients with Chronic Non-infectious Anterior Uveitis
Jul 21, 2017 09:36AM AbbVie Receives CHMP Positive Opinion for HUMIRA® (adalimumab) for the Treatment of Pediatric Patients with Chronic Non-infectious Anterior Uveitis
Jul 10, 2017 08:01AM AbbVie to Host Second-Quarter 2017 Earnings Conference Call
Jun 23, 2017 08:49AM AbbVie (ABBV) Provided a Positive Opinion for MAVIRET (glecaprevir/pibrentasvir) for the Treatment of Chronic Hepatitis C in All Major Genotypes (GT1-6) by CHMP at EMA
Jun 23, 2017 08:47AM AbbVie Receives CHMP Positive Opinion for MAVIRET™ (glecaprevir/pibrentasvir) for the Treatment of Chronic Hepatitis C in All Major Genotypes (GT1-6)
Jun 22, 2017 03:52PM AbbVie Declares Quarterly Dividend
Jun 13, 2017 08:32AM AbbVie (ABBV) Enters Collaboration on Oral Immunoproteasome Inhibitors with Principia
Jun 13, 2017 08:30AM AbbVie and Principia Announce Collaboration on Oral Immunoproteasome Inhibitors
Jun 7, 2017 07:59AM AbbVie (ABBV) Says Upadacitinib (ABT-494) Met All Primary and Ranked Secondary Endpoints in Phase 3 Study in RA
Jun 7, 2017 07:56AM AbbVie's Upadacitinib (ABT-494) Meets All Primary and Ranked Secondary Endpoints in Phase 3 Study in Rheumatoid Arthritis
Jun 5, 2017 07:03AM AbbVie (ABBV) Presents New Data on IMBRUVICA (ibrutinib); May Offer a More Targeted Approach to Chronic Lymphocytic Leukemia (CLL) Treatment than Chemotherapy Agent Chlorambucil
Jun 5, 2017 07:02AM AbbVie (ABBV) Announces Long-Term IMBRUVICA Efficacy and Safety Data in CLL/SLL at ASCO
Jun 5, 2017 07:00AM Long-Term IMBRUVICA® (ibrutinib) Efficacy and Safety Data at ASCO 2017 Show Sustained Survival Rates in Up to Four Years in Previously-Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
Jun 5, 2017 07:00AM New Data Presented at ASCO 2017 Finds IMBRUVICA® (ibrutinib) May Offer a More Targeted Approach to Chronic Lymphocytic Leukemia (CLL) Treatment than Chemotherapy Agent Chlorambucil in Treatment-Naïv
May 24, 2017 08:00AM AbbVie to Present at the Goldman Sachs 38th Annual Global Healthcare Conference
May 19, 2017 08:00AM AbbVie to Present at the Jefferies 2017 Global Healthcare Conference
May 17, 2017 05:00PM AbbVie to Present Latest Clinical Study Results in Hematology and Solid Tumor Research at the 53rd American Society of Clinical Oncology (ASCO) Annual Meeting
May 17, 2017 12:01PM AbbVie (ABBV) Presents Phase 3 Data on Elagolix at World Congress on Endometriosis
May 17, 2017 12:00PM AbbVie Presents Pivotal Phase 3 Data on Investigational Treatment Elagolix at the World Congress on Endometriosis
May 15, 2017 05:50AM AbbVie (ABBV) Announce IMBRUVICA® (Ibrutinib) Pooled Outcomes Data from Three Phase 3 Studies
May 14, 2017 05:00PM IMBRUVICA® (ibrutinib) Pooled Outcomes Data from Three Phase 3 Studies Suggest Potential Clinical Efficacy in Patients with High-Risk Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL)
May 9, 2017 11:24AM AbbVie (ABBV) Confirms Positive Phase 2 Study Results for Upadacitinib (ABT-494)
May 9, 2017 11:00AM AbbVie Announces Positive Phase 2 Study Results for Upadacitinib (ABT-494), an Investigational JAK1-Selective Inhibitor, in Crohn's Disease
May 5, 2017 12:43PM AbbVie to Present at the UBS Global Healthcare Conference
May 4, 2017 09:00AM AbbVie Demonstrates Leadership in Gastroenterology and Hepatology with New Data and Late-Breaking Studies to be Presented at Digestive Disease Week®
Apr 27, 2017 07:38AM AbbVie Reports First-Quarter 2017 Financial Results
Apr 21, 2017 08:00AM AbbVie to Present at the Deutsche Bank 42nd Annual Health Care Conference
Apr 21, 2017 05:43AM AbbVie (ABBV) Reports High SVR12 Rates with 8 Weeks Treatment of Glecaprevir/Pibrentasvir
Apr 21, 2017 01:00AM Eight Weeks of Treatment with AbbVie's Investigational, Pan-Genotypic Regimen of Glecaprevir/Pibrentasvir (G/P) Achieved High SVR(12) Rates in Challenging to Treat Genotype 3 Chronic Hepatitis C
Apr 20, 2017 07:31AM AbbVie (ABBV) G/P Achieved 99% SVR(12) Rate in Chronic Hepatitis C Patients with Compensated Cirrhosis
Apr 20, 2017 07:30AM AbbVie's Investigational, Pan-Genotypic, Ribavirin-free Regimen of Glecaprevir/Pibrentasvir (G/P) Achieved 99 Percent SVR(12) Rate in Chronic Hepatitis C Patients with Compensated Cirrhosis
Apr 7, 2017 08:01AM AbbVie (ABBV), Neurocrine Biosciences (NBIX) Report Positive Phase 2b Data Showing Elagolix Significantly Reduced Heavy Menstrual Bleeding in Women with Uterine Fibroids
Apr 7, 2017 08:00AM AbbVie Announces Positive Phase 2b Data Demonstrating Investigational Medicine Elagolix Significantly Reduced Heavy Menstrual Bleeding in Women with Uterine Fibroids
Apr 6, 2017 08:00AM AbbVie to Host First-Quarter Earnings Conference Call
Apr 4, 2017 07:01AM AbbVie (ABBV) Announces IMBRUVICA sNDA for Previously Treated Chronic Graft-Versus-Host-Disease (cGVHD) Accepted for Review by U.S. FDA
Apr 4, 2017 07:00AM AbbVie Announces Ibrutinib (IMBRUVICA®) Supplemental New Drug Application for Previously Treated Chronic Graft-Versus-Host-Disease (cGVHD) Accepted for Review by U.S. FDA
View More Recent Stories View Older Stories